DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Filoviridae are 1054

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0068	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_0069	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28240606
DrugRepV_0070	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28240606
DrugRepV_0073	Sunitinib-Erlotinib	NA	NA	Ebola virus	rVSV-GP EBOV	NA	Flow cytometry	Decrease	NA	28240606
DrugRepV_0074	Sunitinib-Erlotinib	NA	NA	Ebola virus	Mouse adapted strain	NA	NA	Increase	NA	28240606
DrugRepV_0198	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27890675
DrugRepV_0199	Chloroquine	Antiparasitic products, Insectisides and Repellents	malaria	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27890675
DrugRepV_0200	Maprotiline	Nervous System	Bipolar depression	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27890675
DrugRepV_0201	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27890675
DrugRepV_0202	Azithromycin	Antiinfectives For Systemic Use	Microbial infections	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27890675
DrugRepV_0203	Clarithromycin	Antiinfectives For Systemic Use	Microbial infections	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27890675
DrugRepV_0204	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational, Vet approved	27890675
DrugRepV_0205	Toremifene-Clarithromycin-Posaconazole	NA	NA	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	NA	27890675
DrugRepV_0206	Toremifene-Mefloquine-Posaconazole	NA	NA	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	NA	27890675
DrugRepV_0207	Chloroquine-Maprotiline-Azithromycin	NA	Malaria and Depression	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27890675
DrugRepV_0208	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27890675
DrugRepV_0209	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational, Vet approved	27890675
DrugRepV_0210	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27890675
DrugRepV_0211	Clarithromycin	Antiinfectives For Systemic Use	Microbial infections	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27890675
DrugRepV_0212	Maprotiline	Nervous System	Bipolar depression	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27890675
DrugRepV_0213	Toremifene-Clarithromycin-Posaconazole	NA	NA	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (>90 %)	NA	27890675
DrugRepV_0214	Toremifene-Mefloquine-Posaconazole	NA	NA	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (74 %)	NA	27890675
DrugRepV_0215	Ouabain	Cardiovascular agents	Atrial fibrillation and flutter | Heart failure	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (3.48 ± 0.21 Ct)	Approved	27801778
DrugRepV_0216	Ouabain	Cardiovascular agents	Atrial fibrillation and flutter | Heart failure	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?3.73 ± 4.88 Ct)	Approved	27801778
DrugRepV_0217	Alvespimycin	NA	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (3.72 ± 0.18 Ct)	Investigational	27801778
DrugRepV_0218	Alvespimycin	NA	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?0.63 ± 1.39 Ct)	Investigational	27801778
DrugRepV_0219	Bemcentinib	Anticancer	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (3.05 ± 0.75 Ct)	Investigational	27801778
DrugRepV_0220	Bemcentinib	Anticancer	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?1.83 ± 1.13 Ct)	Investigational	27801778
DrugRepV_0221	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?3.12 ± 0.27 Ct)	Approved	27801778
DrugRepV_0222	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?7.91 ± 2.67 Ct)	Approved	27801778
DrugRepV_0223	Didanosine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?0.43 ± 3.87 Ct)	Approved	27801778
DrugRepV_0224	Didanosine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.52 ± 1.27 Ct)	Approved	27801778
DrugRepV_0225	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.87 ± 0.22 Ct)	Approved, Investigational	27801778
DrugRepV_0226	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?3.93 ± 0.25 Ct)	Approved, Investigational	27801778
DrugRepV_0227	Abacavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?1.54 ± 3.26 Ct)	Approved	27801778
DrugRepV_0228	Abacavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?3.95 ± 2.69 Ct)	Approved	27801778
DrugRepV_0229	Entecavir	Antiinfectives For Systemic Use	Hepatitis B virus	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?3.08 ± 0.20 Ct)	Approved	27801778
DrugRepV_0230	Entecavir	Antiinfectives For Systemic Use	Hepatitis B virus	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?4.44 ± 1.11 Ct)	Approved	27801778
DrugRepV_0231	JB1a	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?4.02 ± 0.13 Ct)	NA	27801778
DrugRepV_0232	JB1a	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?5.48 ± 0.50 Ct)	NA	27801778
DrugRepV_0233	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (1.35 ± 1.35 Ct)	Approved	27801778
DrugRepV_0234	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (2.21 ± 1.08 Ct)	Approved	27801778
DrugRepV_0235	Esomeprazole Magnesium	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (1.05 ± 0.79 Ct)	Approved	27801778
DrugRepV_0236	Esomeprazole Magnesium	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (1.62 ± 0.36 Ct)	Approved	27801778
DrugRepV_0237	Gleevec	Antineoplastic and Immunomodulating Agents	Leukemia	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (3.60 ± 0.63 Ct)	Approved	27801778
DrugRepV_0238	Gleevec	Antineoplastic and Immunomodulating Agents	Leukemia	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (3.49 ± 0.54 Ct)	Approved	27801778
DrugRepV_0239	Aimspro	NA	Multiple sclerosis	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.03 ± 0.95 Ct)	Phase II	27801778
DrugRepV_0240	Aimspro	NA	Multiple sclerosis	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?4.60 ± 1.15 Ct)	Phase II	27801778
DrugRepV_0241	NCK-8	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (>10 Ct)	NA	27801778
DrugRepV_0242	NCK-8	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (>10 Ct)	NA	27801778
DrugRepV_0243	D-LANA-14	Antibacterial	Bacterial infections	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (>10 Ct)	NA	27801778
DrugRepV_0244	D-LANA-14	Antibacterial	Bacterial infections	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (>10 Ct)	NA	27801778
DrugRepV_0245	Tasigna	Antineoplastic and Immunomodulating Agents	Myeloid leukemia	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (3.59 ± 0.57 Ct)	Approved, Investigational	27801778
DrugRepV_0246	Tasigna	Antineoplastic and Immunomodulating Agents	Myeloid leukemia	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?0.13 ± 0.33 Ct)	Approved, Investigational	27801778
DrugRepV_0247	Celgosivir	Antiviral	Hepatitis C virus	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.52 ± 0.21 Ct)	Investigational	27801778
DrugRepV_0248	Celgosivir	Antiviral	Hepatitis C virus	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.41 ± 0.12 Ct)	Investigational	27801778
DrugRepV_0249	Castanospermine	Antiviral	Dengue and Parainfluenza	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?1.58 ± 3.23 Ct)	Experimental	27801778
DrugRepV_0250	Castanospermine	Antiviral	Dengue and Parainfluenza	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?0.26 ± 4.11 Ct)	Experimental	27801778
DrugRepV_0251	Ouabain	Cardiovascular agents	Atrial fibrillation and flutter | Heart failure	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (0.33 ± 0.35 Ct)	Approved	27801778
DrugRepV_0252	Alvespimycin	NA	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (0.44 ± 0.06 Ct)	Investigational	27801778
DrugRepV_0253	Bemcentinib	Anticancer	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (0.90 ± 0.15 Ct)	Investigational	27801778
DrugRepV_0254	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (0.86 ± 0.22 Ct)	Approved	27801778
DrugRepV_0255	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (0.78 ± 0.25 Ct)	Approved	27801778
DrugRepV_0256	Gleevec	Antineoplastic and Immunomodulating Agents	Leukemia	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (1.55 ± 0.20 Ct)	Approved	27801778
DrugRepV_0257	NCK-8	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (1.54 ± 0.44 Ct)	NA	27801778
DrugRepV_0258	D-LANA-14	Antibacterial	Bacterial infections	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (0.96 ± 0.19 Ct)	NA	27801778
DrugRepV_0259	Alvespimycin	NA	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	NA	No significant effect	Investigational	27801778
DrugRepV_0260	Bemcentinib	Anticancer	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	NA	No significant effect	Investigational	27801778
DrugRepV_0261	NCK-8	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	NA	No significant effect	NA	27801778
DrugRepV_0317	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational, Vet approved	27622822
DrugRepV_0318	Mebendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis (Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections)	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Vet approved	27622822
DrugRepV_0319	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0320	Procainamide	Cardiovascular agents	Ventricular arrhythmias	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0321	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0322	Chlortetracycline	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0323	Clemastine	Respiratory System	Sneezing, rhinorrhea, pruritus and acrimation	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0324	Benztropine	Nervous System	Parkinson disease	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0325	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0326	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0327	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0328	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0329	Vincristine	Antineoplastic and Immunomodulating Agents	Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors)	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0330	Thiothixene	Nervous System	Schizophrenia	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0331	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Vet approved	27622822
DrugRepV_0332	Fluphenazine	Nervous System	Psychosis	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0333	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0334	Promazine	Nervous System	Psychomotor agitation	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Vet approved	27622822
DrugRepV_0335	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27622822
DrugRepV_0336	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0337	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0338	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0339	Mebendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis (Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections)	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved, Vet approved	27622822
DrugRepV_0340	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0341	Procainamide	Cardiovascular agents	Ventricular arrhythmias	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0342	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0343	Chlortetracycline	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0344	Benztropine	Nervous System	Parkinson disease	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0345	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0346	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0347	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0348	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0349	Vincristine	Antineoplastic and Immunomodulating Agents	Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors)	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0350	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0351	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved, Investigational	27622822
DrugRepV_0352	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0353	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire	NA	Survival assay	Increase	Approved	27622822
DrugRepV_0354	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0355	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Ebola Zaire	NA	Survival assay	Increase	Approved	27622822
DrugRepV_0356	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0357	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	Ebola Zaire	NA	Survival assay	Increase	Approved	27622822
DrugRepV_0358	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0359	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0360	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0361	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0362	Benztropine	Nervous System	Parkinson disease	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0363	Benztropine	Nervous System	Parkinson disease	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0364	Chlortetracycline	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0365	Chlortetracycline	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0366	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Mayinga	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0367	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Ebola Mayinga	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0368	Amlodipine Besylate	Cardiovascular agents	Hypertension and chronic stable angina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0369	Azelastine	Respiratory System	Rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0370	Benztropine Mesylate	Nervous System	Parkinson disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0371	Cephapirin Sodium	Antibiotics	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0372	Chlorhexidine Diacetate	Alimentary Tract and Metabolism	Disinfectant, oropharyngeal decontamination	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0373	Ciclesonide	Respiratory System	Allergic rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0374	Cilastatin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0375	Clemastine Fumarate	Respiratory System	Allergic rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0376	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0377	Clomipramine Hydrochloride	Nervous System	Obsessive-compulsive disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0378	Danazol	Genito Urinary System and Sex Hormones	Endometriosis and fibrocystic breast disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0379	Deslanoside	Cardiovascular agents	Congestive cardiac insufficiency, arrhythmias and heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0380	Dicyclomine Hydrochloride	Alimentary Tract and Metabolism	Bowel/irritable bowel syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0381	Digitoxin	Cardiovascular agents	Cardiac insufficiency, arrhythmias and heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0382	Digoxin	Cardiovascular agents	Cardiac insufficiency, arrhythmias and heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0383	Doxylamine Succinate	Respiratory System	Cough, vomiting and nausea	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0384	Flucytosine	Antiinfectives For Systemic Use	Fungal infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0385	Fluphenazine Hydrochloride	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0386	Fluvastatin	Cardiovascular agents	Cardiovascular disease (Coronary heart disease (CHD))	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0387	Guanethidine Monosulfate	Cardiovascular agents	Hypertension	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0388	Hexachlorophene	Dermatologicals	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0389	Hycanthone	Antischistosomal	Parasitic infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0390	Hydroxyprogesterone Caproate	Genito Urinary System and Sex Hormones	Spontaneous preterm births	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0391	Loperamide	Alimentary Tract and Metabolism	Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0392	Maprotiline Hydrochloride	Nervous System	Bipolar depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0393	Mebendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis (Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Vet approved	26041706
DrugRepV_0394	Methdilazine Hydrochloride	Respiratory System	Hypersensitivity reactions | Skin disorders	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0395	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0396	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0397	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0398	Nonoxynol-9	Gynaecological-agents	Contraception	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0399	Paroxetine Hydrochloride Hemihydrate	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0400	Pentamidine	Antiparasitic products, Insectisides and Repellents	Pneumonia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0401	Perhexiline Maleate	Cardiovascular agents	Angina pectoris	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0402	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0403	Podofilox	Dermatologicals	External genital warts	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0404	Prochlorperazine Edisylate	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Vet approved	26041706
DrugRepV_0405	Pyrvinium Pamoate	Antiparasitic products, Insectisides and Repellents	Pinworm infestations	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0406	Quinacrine Dihydrochloride	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	26041706
DrugRepV_0407	Quinestrol	Gynaecological-agents	Hormone replacement therapy | Treating symptoms of menopause such as hot flashes | Breast cancer | Prostate cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0408	Raloxifene Hydrochloride	Genito Urinary System and Sex Hormones	Osteoporosis | Corticosteroid-induced bone loss	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0409	Sertraline Hydrochloride	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0410	Sorafenib Tosylate	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma | Renal cell carcinoma	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0411	Sunitinib Malate	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0412	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0413	Tamoxifen Citrate	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0414	Thioridazine Hydrochloride	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0415	Tioconazole	Dermatologicals; Genito Urinary System and Sex Hormones	Vulvovaginal candidiasis (moniliasis)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0416	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0417	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0418	Trifluoperazine Hydrochloride	Nervous System	Schizophrenia and other psychotic disorders	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0419	Triflupromazine Hydrochloride	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0420	Vinorelbine Tartrate Hydrate	Antineoplastic and Immunomodulating Agents	Breast cancer and non-small cell lung cancer (NSCLC)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	NA	26041706
DrugRepV_0421	Aripiprazole	Nervous System	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0422	Astemizole	Respiratory System	Allergies	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0423	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0424	Azacitidine	Antineoplastic and Immunomodulating Agents	French-American-British myelodysplastic syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0425	Benztropine	Nervous System	Parkinson disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0426	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0427	Clemastine	Respiratory System	Allergic rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0428	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0429	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0430	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0431	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0432	Flupentixol	Nervous System	Schizophrenia | Depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Withdrawn	26041706
DrugRepV_0433	Fluphenazine	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0434	Hycanthone	Antischistosomal	Parasitic infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0435	Lomerizine	Neurologic-agent	Migraine disorders	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0436	Maprotiline	Nervous System	Bipolar depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0437	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0438	Pimozide	Nervous System	Tourette Disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0439	Piperacetazine	Antipsychotic	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	NA	26041706
DrugRepV_0440	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0441	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	26041706
DrugRepV_0442	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0443	Simvastatin	Cardiovascular agents	Hypercholesterolemia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0444	Strophanthin	Cardiovascular agents	Atrial fibrillation | Flutter | Heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0445	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0446	Terconazole	Genito Urinary System and Sex Hormones	Candidiasis (a yeast-like fungal infection) of the vulva and vagina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0447	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0448	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0449	Aripiprazole	Nervous System	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0450	Astemizole	Respiratory System	Allergies	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0451	Azacitidine	Antineoplastic and Immunomodulating Agents	French-American-British myelodysplastic syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0452	Benztropine	Nervous System	Parkinson disease	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0453	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0454	Clemastine	Respiratory System	Allergic rhinitis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0455	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0456	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0457	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0458	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0459	Flupentixol	Nervous System	Schizophrenia | Depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Withdrawn	26041706
DrugRepV_0460	Fluphenazine	Nervous System	Psychosis	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0461	Hycanthone	Antischistosomal	Parasitic infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0462	Lomerizine	Neurologic-agent	Migraine disorders	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26041706
DrugRepV_0463	Maprotiline	Nervous System	Bipolar depression	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0464	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0465	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0466	Pimozide	Nervous System	Tourette Disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0467	Piperacetazine	Antipsychotic	Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	NA	26041706
DrugRepV_0468	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0469	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	26041706
DrugRepV_0470	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0471	Strophanthin	Cardiovascular agents	Atrial fibrillation | Flutter | Heart failure	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0472	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0473	Terconazole	Genito Urinary System and Sex Hormones	Candidiasis (a yeast-like fungal infection) of the vulva and vagina	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0474	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0475	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0476	Vinorelbine	Antineoplastic and Immunomodulating Agents	Breast cancer and non-small cell lung cancer (NSCLC)	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0477	Aripiprazole	Nervous System	Schizophrenia	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0478	Astemizole	Respiratory System	Allergies	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Withdrawn	26041706
DrugRepV_0479	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOV-VLP	NA	Flow cytometry	No significant effect	Approved	26041706
DrugRepV_0480	Azacitidine	Antineoplastic and Immunomodulating Agents	French-American-British myelodysplastic syndrome	Ebola virus	EBOV-VLP	NA	Flow cytometry	No significant effect	Approved	26041706
DrugRepV_0481	Benztropine	Nervous System	Parkinson disease	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0482	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Withdrawn	26041706
DrugRepV_0483	Clemastine	Respiratory System	Allergic rhinitis	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0484	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0485	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0486	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0487	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0488	Flupentixol	Nervous System	Schizophrenia | Depression	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Investigational, Withdrawn	26041706
DrugRepV_0489	Fluphenazine	Nervous System	Psychosis	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0490	Hycanthone	Antischistosomal	Parasitic infections	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Experimental	26041706
DrugRepV_0491	Lomerizine	Neurologic-agent	Migraine disorders	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Experimental	26041706
DrugRepV_0492	Maprotiline	Nervous System	Bipolar depression	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Investigational	26041706
DrugRepV_0493	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Ebola virus	EBOV-VLP	NA	Flow cytometry	No significant effect	Approved, Investigational	26041706
DrugRepV_0494	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Investigational	26041706
DrugRepV_0495	Pimozide	Nervous System	Tourette Disorder	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0496	Piperacetazine	Antipsychotic	Schizophrenia	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	NA	26041706
DrugRepV_0497	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0498	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	EBOV-VLP	NA	Flow cytometry	No significant effect	Investigational	26041706
DrugRepV_0499	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0500	Simvastatin	Cardiovascular agents	Hypercholesterolemia	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0501	Strophanthin	Cardiovascular agents	Atrial fibrillation | Flutter | Heart failure	Ebola virus	EBOV-VLP	NA	Flow cytometry	No significant effect	Approved	26041706
DrugRepV_0502	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0503	Terconazole	Genito Urinary System and Sex Hormones	Candidiasis (a yeast-like fungal infection) of the vulva and vagina	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0504	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Withdrawn	26041706
DrugRepV_0505	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved, Investigational	26041706
DrugRepV_0506	Vinorelbine	Antineoplastic and Immunomodulating Agents	Breast cancer and non-small cell lung cancer (NSCLC)	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0507	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	ma-EBOV	NA	Survival assay	Increase	Approved, Withdrawn	26041706
DrugRepV_0508	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	ma-EBOV	NA	Survival assay	Increase	Approved	26041706
DrugRepV_0509	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	EBOV/Kik	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0510	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	SUDV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0511	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	MARV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0512	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	RAVV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Withdrawn	26041706
DrugRepV_0513	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV/Kik	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0514	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV/May	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0515	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	SUDV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0516	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	MARV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0517	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	RAVV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0518	Vinblastine	Antineoplastic and Immunomodulating Agents	Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0519	Vinorelbine	Antineoplastic and Immunomodulating Agents	Breast cancer and non-small cell lung cancer (NSCLC)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0520	Vincristine	Antineoplastic and Immunomodulating Agents	Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0521	Colchicine	Musculo-Skeletal System	Gout	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0522	Nocodazole	Anticancer	NA	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26038505
DrugRepV_0523	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0524	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0525	Digoxin	Cardiovascular agents	Cardiac insufficiency, arrhythmias and heart failure	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0526	Clemastine	Respiratory System	Allergic rhinitis	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0527	Raloxifene/Evista	Genito Urinary System and Sex Hormones	Osteoporosis | Corticosteroid-induced bone loss	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0528	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0529	Thiothixene	Nervous System	Schizophrenia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0530	Dronedarone	Cardiovascular agents	Arrhythmia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0531	Maprotiline	Nervous System	Bipolar depression	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0532	Daunorubicin	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0533	Benztropine	Nervous System	Parkinson disease	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0534	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0535	Mebendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis (Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Vet approved	26038505
DrugRepV_0536	Trifluoperazine	Nervous System	Schizophrenia and other psychotic disorders	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0537	Clarithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0538	Albendazole	Antiparasitic products, Insectisides and Repellents	Parasitic infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0539	Clomipramine	Nervous System	Depressive disorder	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0540	Propafenone	Cardiovascular agents	Arrhythmia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0541	Carfilzomib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0542	Deslanoside	Cardiovascular agents	Arrhythmia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0543	Maduramicin	Antiprotozoal	Coccidiosis	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Vet approved	26038505
DrugRepV_0544	Cepharanthine	Antiinflammatory and antineoplastic	Inflammatory disorders/Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0545	Clomiphene	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0546	Oxibendazole	Antiparasitic	Helminth intestinal infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Investigational, Vet approved	26038505
DrugRepV_0547	Daunorubicin	Antineoplastic and Immunomodulating Agents	Microbial infections and cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0548	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0549	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0550	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0551	Tilorone	NA	Acquired immunodeficiency syndrome	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0552	Bazedoxifene	Genito Urinary System and Sex Hormones	Postmenopausal osteoporosis	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0553	Topotecan	Antineoplastic and Immunomodulating Agents	Ovarian cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0554	Bosutinib	Antineoplastic and Immunomodulating Agents	Cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0555	Thioproperazine	Nervous System	Psychosis | Acute and Chronic schizophrenia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0556	Spiramycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0557	Mibefradil	Cardiovascular agents	Angina | High blood pressure	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Investigational, Withdrawn	26038505
DrugRepV_0558	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0559	Nitrovin	NA	NA	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0560	Bifemelane	Nervous System	Depressive disorder	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26038505
DrugRepV_0561	Bitolterol	Respiratory System	Bronchodilator	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Withdrawn	26038505
DrugRepV_0562	Proglumetacin	Musculo-Skeletal System	Inflammatory disorders	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Experimental	26038505
DrugRepV_0563	Aprindine	Cardiovascular agents	Arrhythmia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0564	Cyclomethycaine	NA	Anesthesia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Withdrawn	26038505
DrugRepV_0565	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Vet approved	26038505
DrugRepV_0566	Alverine Citrate	Alimentary Tract and Metabolism	Muscle spasms	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0567	Azaclorzine	NA	Anginal	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0568	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0569	Piperacetazine	Antipsychotic	Schizophrenia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0570	Gefitinib	Antineoplastic and Immunomodulating Agents	Non-small cell lung cancer	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0571	Imipramine	Nervous System	Depression	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0572	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0573	Nilotinib	Antineoplastic and Immunomodulating Agents	Leukemias | Chronic myeloid leukemia (CML)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26038505
DrugRepV_0581	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23785035
DrugRepV_0582	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23785035
DrugRepV_0583	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0584	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0585	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	EBOV/Kik	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	23785035
DrugRepV_0586	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	EBOV/May	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	23785035
DrugRepV_0587	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	SUDV	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	23785035
DrugRepV_0588	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	MARV	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	23785035
DrugRepV_0589	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	RAVV	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	23785035
DrugRepV_0590	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOV/Kik	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0591	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOV/May	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0592	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	SUDV	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0593	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	MARV	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0594	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	RAVV	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0595	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	EBOV/Kik	NA	Real-time PCR	Decrease (50 %)	Approved	23785035
DrugRepV_0596	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	SUDV	NA	Real-time PCR	Decrease (50 %)	Approved	23785035
DrugRepV_0597	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	MARV	NA	Real-time PCR	Decrease (50 %)	Approved	23785035
DrugRepV_0598	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOV/Kik	NA	Real-time PCR	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0599	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	SUDV	NA	Real-time PCR	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0600	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	MARV	NA	Real-time PCR	Decrease (50 %)	Approved, Investigational	23785035
DrugRepV_0601	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	ma-EBOV	NA	NA	Increase	Approved	23785035
DrugRepV_0602	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	ma-EBOV	NA	NA	Increase	Approved, Investigational	23785035
DrugRepV_0603	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	VLP-GP	NA	Flow cytometry	Decrease (93 %)	Approved	23785035
DrugRepV_0604	Toremifene Citrate	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	VLP-GP	NA	Flow cytometry	Decrease (95 %)	Approved, Investigational	23785035
DrugRepV_0644	Amlodipine	Cardiovascular agents	Hypertension	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (93 %)	Approved	23577127
DrugRepV_0645	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (97 %)	Approved	23577127
DrugRepV_0646	Biperiden	Nervous System	Parkinson disease	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (89 %)	Approved	23577127
DrugRepV_0647	Carprofen	Anti-inflammatory	Joint pain	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (88 %)	Approved, Withdrawn	23577127
DrugRepV_0648	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (97 %)	Approved	23577127
DrugRepV_0649	Dexbrompheniramine	Respiratory System	Allergies	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (80 %)	Approved	23577127
DrugRepV_0650	Dibucaine	Nervous System	Anesthesia	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (93 %)	Approved	23577127
DrugRepV_0651	Diphenoxylate	Alimentary Tract and Metabolism	Diarrhea	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (95 %)	Approved	23577127
DrugRepV_0652	Diphenylpyraline	Respiratory System	Allergies	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (85 %)	Approved	23577127
DrugRepV_0653	Dipivefrin	Sensory Organ	Glaucoma	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (90 %)	Approved	23577127
DrugRepV_0654	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (91 %)	Approved	23577127
DrugRepV_0655	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved	23577127
DrugRepV_0656	Estradiol	Genito Urinary System and Sex Hormones	Vulvar and vaginal atrophy	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved	23577127
DrugRepV_0657	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved, Vet approved	23577127
DrugRepV_0658	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (97 %)	Approved	23577127
DrugRepV_0659	Levopropoxyphene	Respiratory-Tract-agents	Cough and associated respiratory tract disorders	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (89 %)	Withdrawn	23577127
DrugRepV_0660	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (81 %)	Approved, Investigational	23577127
DrugRepV_0661	Oxyphencyclimine	Alimentary Tract and Metabolism	Peptic ulcers	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (89 %)	Approved	23577127
DrugRepV_0662	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (89 %)	Approved, Investigational	23577127
DrugRepV_0663	Penbutolol	Cardiovascular agents	Arterial hypertension	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (81 %)	Approved, Investigational	23577127
DrugRepV_0664	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (93 %)	Approved	23577127
DrugRepV_0665	Protriptyline	Nervous System	Depressive disorder	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (80 %)	Approved	23577127
DrugRepV_0666	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (96 %)	Approved, Investigational	23577127
DrugRepV_0667	Trihexyphenidyl	Nervous System	Parkinson Disease	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (91 %)	Approved	23577127
DrugRepV_0668	Amlodipine	Cardiovascular agents	Hypertension	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (93 %)	Approved	23577127
DrugRepV_0669	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (99 %)	Approved	23577127
DrugRepV_0670	Biperiden	Nervous System	Parkinson disease	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved	23577127
DrugRepV_0671	Carprofen	Anti-inflammatory	Joint pain	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (94 %)	Approved, Withdrawn	23577127
DrugRepV_0672	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (97 %)	Approved	23577127
DrugRepV_0673	Dexbrompheniramine	Respiratory System	Allergies	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (85 %)	Approved	23577127
DrugRepV_0674	Dibucaine	Nervous System	Anesthesia	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (99 %)	Approved	23577127
DrugRepV_0675	Diphenoxylate	Alimentary Tract and Metabolism	Diarrhea	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (96 %)	Approved	23577127
DrugRepV_0676	Diphenylpyraline	Respiratory System	Allergies	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (96 %)	Approved	23577127
DrugRepV_0677	Dipivefrin	Sensory Organ	Glaucoma	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (94 %)	Approved	23577127
DrugRepV_0678	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (99 %)	Approved	23577127
DrugRepV_0679	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (96 %)	Approved	23577127
DrugRepV_0680	Estradiol	Genito Urinary System and Sex Hormones	Vulvar and vaginal atrophy	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (93 %)	Approved	23577127
DrugRepV_0681	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (96 %)	Approved, Vet approved	23577127
DrugRepV_0682	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (99 %)	Approved	23577127
DrugRepV_0683	Levopropoxyphene	Respiratory-Tract-agents	Cough and associated respiratory tract disorders	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Withdrawn	23577127
DrugRepV_0684	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (91 %)	Approved, Investigational	23577127
DrugRepV_0685	Oxyphencyclimine	Alimentary Tract and Metabolism	Peptic ulcers	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (95 %)	Approved	23577127
DrugRepV_0686	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved, Investigational	23577127
DrugRepV_0687	Penbutolol	Cardiovascular agents	Arterial hypertension	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved, Investigational	23577127
DrugRepV_0688	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (95 %)	Approved	23577127
DrugRepV_0689	Protriptyline	Nervous System	Depressive disorder	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (83 %)	Approved	23577127
DrugRepV_0690	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (97 %)	Approved, Investigational	23577127
DrugRepV_0691	Trihexyphenidyl	Nervous System	Parkinson Disease	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (97 %)	Approved	23577127
DrugRepV_0692	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0693	Biperiden	Nervous System	Parkinson disease	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0694	Carprofen	Anti-inflammatory	Joint pain	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Withdrawn	23577127
DrugRepV_0695	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease	Approved	23577127
DrugRepV_0696	Dibucaine	Nervous System	Anesthesia	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0697	Diphenoxylate	Alimentary Tract and Metabolism	Diarrhea	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease	Approved	23577127
DrugRepV_0698	Diphenylpyraline	Respiratory System	Allergies	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease	Approved	23577127
DrugRepV_0699	Dipivefrin	Sensory Organ	Glaucoma	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0700	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0701	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0702	Estradiol	Genito Urinary System and Sex Hormones	Vulvar and vaginal atrophy	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0703	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Vet approved	23577127
DrugRepV_0704	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease	Approved	23577127
DrugRepV_0705	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Investigational	23577127
DrugRepV_0706	Oxyphencyclimine	Alimentary Tract and Metabolism	Peptic ulcers	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0707	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved, Investigational	23577127
DrugRepV_0708	Trihexyphenidyl	Nervous System	Parkinson Disease	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0709	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (50 %)	Approved	23577127
DrugRepV_0710	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Marburg virus	GP derived Pseudovirus	NA	Luciferase virus entry activity	Decrease (50 %)	Approved	23577127
DrugRepV_0711	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (50 %)	Approved	23577127
DrugRepV_0712	Aminoquinoline-13	NA	Malaria	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (50 %)	NA	23577127
DrugRepV_0713	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Marburg virus	Musoke	NA	Immunoflourescence assay	Decrease (50 %)	Approved	23577127
DrugRepV_0714	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Marburg virus	Musoke	NA	Immunoflourescence assay	Decrease (50 %)	Approved	23577127
DrugRepV_0715	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Marburg virus	Musoke	NA	Immunoflourescence assay	Decrease (50 %)	Approved	23577127
DrugRepV_0716	Aminoquinoline-13	NA	Malaria	Marburg virus	Musoke	NA	Immunoflourescence assay	Decrease (50 %)	NA	23577127
DrugRepV_0717	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (50 %)	Approved	23577127
DrugRepV_0718	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (50 %)	Approved	23577127
DrugRepV_0719	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (50 %)	Approved	23577127
DrugRepV_0720	Aminoquinoline-13	NA	Malaria	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (50 %)	NA	23577127
DrugRepV_0721	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23577127
DrugRepV_0722	Hydroxychloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23577127
DrugRepV_0723	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease (50 %)	Approved	23577127
DrugRepV_0724	Aminoquinoline-13	NA	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease (50 %)	NA	23577127
DrugRepV_0725	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0726	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	ma-EBOV	NA	NA	Increase	Approved	23577127
DrugRepV_0727	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0728	Erythromycin ethylsuccinate	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0729	Amlodipine	Cardiovascular agents	Hypertension	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0730	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved, Vet approved	23577127
DrugRepV_0731	Penbutolol	Cardiovascular agents	Arterial hypertension	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved, Investigational	23577127
DrugRepV_0756	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Increase (7 %)	Investigational	26930627
DrugRepV_0757	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	Real-time PCR	No significant effect	Investigational	26930627
DrugRepV_0758	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Decrease (33 %)	Investigational	26930627
DrugRepV_0759	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	Real-time PCR	Decrease	Investigational	26930627
DrugRepV_1615	Quinacrine Hydrochloride	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	Recombinant, infectious Ebola virus encoding green fluorescent protein	NA	Cell based assay	Decrease (50 %)	Investigational	26834994
DrugRepV_1616	Pyronaridine tetraphosphate	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Recombinant, infectious Ebola virus encoding green fluorescent protein	NA	Cell based assay	Decrease (50 %)	Approved	26834994
DrugRepV_1617	Tilorone Dihydrochloride	NA	Viral infections	Ebola virus	Recombinant, infectious Ebola virus encoding green fluorescent protein	NA	Cell based assay	Decrease (50 %)	NA	26834994
DrugRepV_1618	Chloroquine Diphosphate	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Recombinant, infectious Ebola virus encoding green fluorescent protein	NA	Cell based assay	Decrease (50 %)	Approved	26834994
DrugRepV_2015	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2016	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2017	Clemastine	Respiratory System	Allergic rhinitis	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2018	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved, Investigational	26585243
DrugRepV_2019	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved, Investigational	26585243
DrugRepV_2020	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved, Investigational	26585243
DrugRepV_2021	Clomiphene	Genito Urinary System and Sex Hormones	Cancer	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2022	Securinine	Anticancer	NA	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	NA	26585243
DrugRepV_2023	Glafenine	Nervous System	Inflammatory disease	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	NA	26585243
DrugRepV_2024	Oxeladin	Respiratory-Tract-agents	Cough	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Withdrawn	26585243
DrugRepV_2025	Pimethixene Maleate	Respiratory System	NA	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2026	Artemisinin	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Experimental	26585243
DrugRepV_2027	Indoprofen	Musculo-Skeletal System	Inflammatory disease	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Withdrawn	26585243
DrugRepV_2028	Iodoquinol	Genito Urinary System and Sex Hormones	Amoebiasis	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2029	Levonordefrin	NA	Dental disorders	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2030	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (90 %)	Approved	26585243
DrugRepV_2031	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2032	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (87.5 %)	Approved	26585243
DrugRepV_2033	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (95 %)	Approved	26585243
DrugRepV_2034	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	No significant effect (0 %)	Approved	26585243
DrugRepV_2071	Diphenhydramine	Dermatologicals and Respiratory System	Vertigo/Meniere's disease, nausea and vomiting, motion sickness and insect bite	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2072	Chlorcyclizine	Respiratory System	Allergic rhinitis	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2073	Diphenhydramine	Dermatologicals and Respiratory System	Vertigo/Meniere's disease, nausea and vomiting, motion sickness and insect bite	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2074	Chlorcyclizine	Respiratory System	Allergic rhinitis	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2075	Cetirizine	Respiratory System	Allergic rhinitis	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	No significant decrease (50 %)	Approved	29981374
DrugRepV_2076	Cetirizine	Respiratory System	Allergic rhinitis	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	No significant decrease (50 %)	Approved	29981374
DrugRepV_2077	Fexofenadine	Respiratory System	Allergic rhinitis	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	No significant decrease (50 %)	Approved, Investigational	29981374
DrugRepV_2078	Fexofenadine	Respiratory System	Allergic rhinitis	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	No significant decrease (50 %)	Approved, Investigational	29981374
DrugRepV_2079	Tiotidine	NA	NA	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	No significant decrease (50 %)	NA	29981374
DrugRepV_2080	Tiotidine	NA	NA	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	No significant decrease (50 %)	NA	29981374
DrugRepV_2081	Impentamine	NA	NA	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	No significant decrease (50 %)	NA	29981374
DrugRepV_2082	Impentamine	NA	NA	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	No significant decrease (50 %)	NA	29981374
DrugRepV_2083	JNJ7777120	Anti-inflammatory	Pruritus (itching)	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	NA	29981374
DrugRepV_2084	JNJ7777120	Anti-inflammatory	Pruritus (itching)	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	NA	29981374
DrugRepV_2085	Nordiphenhydramine	NA	NA	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	NA	29981374
DrugRepV_2086	Nordiphenhydramine	NA	NA	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	NA	29981374
DrugRepV_2087	Orphenadrine	Nervous System	Parkinson's disease | Muscle spasm	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2088	Orphenadrine	Nervous System	Parkinson's disease | Muscle spasm	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2089	Chlorphenoxamine	Respiratory System	Parkinson's	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Withdrawn	29981374
DrugRepV_2090	Chlorphenoxamine	Respiratory System	Parkinson's	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Withdrawn	29981374
DrugRepV_2091	Carbinoxamine	Respiratory System	Allergic rhinitis	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2092	Carbinoxamine	Respiratory System	Allergic rhinitis	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2093	Doxylamine	Respiratory System	Allergies and an antitussive, antiemetic, and hypnotic	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2094	Doxylamine	Respiratory System	Allergies and an antitussive, antiemetic, and hypnotic	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	No significant decrease (50 %)	Approved	29981374
DrugRepV_2095	Hydroxyzine	Nervous System	Anxiety | Tension	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2096	Hydroxyzine	Nervous System	Anxiety | Tension	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2097	Cyclizine	Respiratory System	Nausea, vomiting, and dizziness	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2098	Cyclizine	Respiratory System	Nausea, vomiting, and dizziness	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2099	Buclizine	Respiratory System	Nausea, vomiting, and dizziness	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2100	Buclizine	Respiratory System	Nausea, vomiting, and dizziness	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2101	Meclizine	Respiratory System	Nausea | Vomiting | Motion sickness | Vertigo	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2102	Meclizine	Respiratory System	Nausea | Vomiting | Motion sickness | Vertigo	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	Approved	29981374
DrugRepV_2103	Diphenhydramine	Dermatologicals and Respiratory System	Vertigo/Meniere's disease, nausea and vomiting, motion sickness and insect bite	Ebola virus	EBOV/kikwit	NA	Immunoblot assay	Decrease (50 %)	Approved	29981374
DrugRepV_2104	Chlorcyclizine	Respiratory System	Allergic rhinitis	Ebola virus	EBOV/kikwit	NA	Immunoblot assay	Decrease (50 %)	Approved	29981374
DrugRepV_2105	Diphenhydramine	Dermatologicals and Respiratory System	Vertigo/Meniere's disease, nausea and vomiting, motion sickness and insect bite	Ebola virus	EBOV/kikwit	NA	Immunoblot assay	Decrease (50 %)	Approved	29981374
DrugRepV_2106	Chlorcyclizine	Respiratory System	Allergic rhinitis	Ebola virus	EBOV/kikwit	NA	Immunoblot assay	Decrease (50 %)	Approved	29981374
DrugRepV_3566	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	EBOV/Mak	NA	Luminescence assay	Decrease (50 %)	Approved, Investigational	30016444
DrugRepV_3567	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	EBOV/Mak	NA	Luminescence assay	Decrease (50 %)	Approved, Investigational	30016444
DrugRepV_3568	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	EBOV/Mak	NA	Luminescence assay	Decrease (50 %)	Approved, Investigational	30016444
DrugRepV_3569	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	EBOV/May-GPA	NA	Luminescence assay	Decrease (50 %)	Approved, Investigational	30016444
DrugRepV_3570	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	EBOV/May-GPA	NA	Luminescence assay	Decrease (50 %)	Approved, Investigational	30016444
DrugRepV_3571	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3572	Trifluoperazine	Nervous System	Schizophrenia and other psychotic disorders	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3573	Clomipramine	Nervous System	Depression, schizophrenia, Tourette disorder	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3574	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	30149038
DrugRepV_3575	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	30149038
DrugRepV_3576	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	30149038
DrugRepV_3577	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3578	AY9944	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3579	Paroxetine	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	30149038
DrugRepV_3580	Thioridazine	Nervous System	Schizophrenia | Anxiety disorder	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Withdrawn	30149038
DrugRepV_3581	GBR-12783	NA	Psychosis	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3582	Tabimorelin	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3583	Asenapine	Nervous System	Psychosis	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3584	Camylofine	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3585	Bisacodyl	Alimentary Tract and Metabolism	Colon cleansing	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3586	Bisacodyl	Alimentary Tract and Metabolism	Colon cleansing	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3587	ML9	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3588	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3589	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved	30149038
DrugRepV_3590	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	30149038
DrugRepV_3591	Bepridil	Cardiovascular agents	Hypertension and angina	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Withdrawn	30149038
DrugRepV_3592	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	30149038
DrugRepV_3593	Iminodyn 17	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3594	Nobiletin	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3595	Ferroquine	Antimalarial	Malaria	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3596	N-Acetyl-L-leucyl- L- leucyl-L- methional	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3597	Calpeptin	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3627	Cyanovirin-N	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	15073681
DrugRepV_3628	Cyanovirin-N	NA	NA	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	15073681
DrugRepV_3629	Cyanovirin-N	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	15073681
DrugRepV_3630	N-methyl-5,7-dinitro-N-propylquinolin-8-amine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3631	2-[3-(4-chlorophenyl)-1-(3-methoxyphenyl)-3-oxopropyl]propanedinitrile	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3632	(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,9,15(20)-pentaene-14,18-dione	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3633	2-[(1E)-2-(5-nitrofuran-2-yl)ethenyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-one	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3634	N-(3,4-dichlorophenyl)-5-nitrofuran-2-carboxamide	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3635	7-[(furan-2-yl)methyl]-3-[3-(1H-imidazol-1-yl)propyl]-5,6-diphenyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-imine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3636	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3637	N,N-bis(4-methylphenyl)pyridin-3-amine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3638	N-methyl-5,7-dinitro-N-propylquinolin-8-amine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3639	2-[3-(4-chlorophenyl)-1-(3-methoxyphenyl)-3-oxopropyl]propanedinitrile	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3640	(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,9,15(20)-pentaene-14,18-dione	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3641	2-[(1E)-2-(5-nitrofuran-2-yl)ethenyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-one	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3642	N-(3,4-dichlorophenyl)-5-nitrofuran-2-carboxamide	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3643	7-[(furan-2-yl)methyl]-3-[3-(1H-imidazol-1-yl)propyl]-5,6-diphenyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-imine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3644	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3645	N,N-bis(4-methylphenyl)pyridin-3-amine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3646	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3647	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3652	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3653	2-methyl-4-phenyl-1H-naphtho[2,3-b][1,4]diazepine hydrochloride	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3654	2-(4-chlorophenyl)-7,8-dimethyl-4-(trifluoromethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3655	2-(1,1,2,2,2-pentafluoroethyl)-4-phenyl-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3656	7,8-dichloro-2-(1,1,2,2,2-pentafluoroethyl)-4-phenyl-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3657	2-[4-(trifluoromethyl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3658	2-(4-methylphenyl)-4-(trifluoromethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3659	4-methoxy-2-[4-(trifluoromethyl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3660	2-[4-(thiophen-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3661	4-chloro-2-[4-(furan-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3662	4-methoxy-2-[4-(thiophen-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3663	2-[4-(furan-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3664	2-[4-(3-nitrophenyl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3665	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	Lake Victoria	NA	Luciferase reporter assay	Decrease (90 %)	NA	21270170
DrugRepV_3666	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	Lake Victoria	NA	Luciferase reporter assay	Decrease (50 %)	NA	21270170
DrugRepV_3667	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	Lake Victoria	NA	Luciferase reporter assay	Decrease (100 %)	NA	21270170
DrugRepV_3668	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	Lake Victoria	NA	Luciferase reporter assay	Decrease (98 %)	NA	21270170
DrugRepV_3671	2,6-bis[(3-tert-butyl-2-hydroxy-5-methylphenyl)methyl]-4-methylphenol	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (100 %)	NA	22027648
DrugRepV_3672	NSC 62914	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease	NA	22027648
DrugRepV_3673	NSC 62914	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	22027648
DrugRepV_3674	Trolox	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (45 %)	NA	22027648
DrugRepV_3675	Trolox	NA	NA	Marburg virus	NA	NA	RT-PCR	Decrease (70 %)	NA	22027648
DrugRepV_3676	NSC 62914	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (98 %)	NA	22027648
DrugRepV_3679	NSC 62914	NA	NA	Ebola virus	NA	NA	NA	Decrease	NA	22027648
DrugRepV_3680	NSC 62914	NA	NA	Marburg virus	NA	NA	NA	Decrease	NA	22027648
DrugRepV_3681	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine tetrahydrochloride	NA	NA	Ebola virus	Zaire-95	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3682	N5,N14-bis[2-(morpholin-4-yl)ethyl]-3,12-bis({[2-(morpholin-4-yl)ethyl]amino})-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-5,14-dicarboxamide; hexakis(trifluoroacet	NA	NA	Ebola virus	Zaire-95	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3683	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine	NA	NA	Ebola virus	Zaire-95	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3684	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine tetrahydrochloride	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3685	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3686	BCX4430	NA	Ebola virus	Marburg virus	Musoke	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3687	BCX4430	NA	Ebola virus	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3688	BCX4430	NA	Ebola virus	Marburg virus	Angola	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3689	BCX4430	NA	Ebola virus	Ebola virus	Kikwit	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3697	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	24713118
DrugRepV_3698	6-Azauridine	NA	Cancer	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	24713118
DrugRepV_3699	2-C-Methylcytidine	NA	Hepatitis C virus	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	Experimental	24713118
DrugRepV_3700	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	24713118
DrugRepV_3701	6-Azauridine	NA	Cancer	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	24713118
DrugRepV_3702	2-C-Methylcytidine	NA	Hepatitis C virus	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Experimental	24713118
DrugRepV_3703	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Marburg virus	NA	NA	NA	Decrease (83 %)	Approved	24713118
DrugRepV_3704	6-Azauridine	NA	Cancer	Marburg virus	NA	NA	NA	Decrease (98 %)	NA	24713118
DrugRepV_3705	Chloroquine	Malaria	Malaria	Marburg virus	NA	NA	NA	Decrease (99.9 %)	Approved	24713118
DrugRepV_3706	Imatinib Methanesulfonate Salt	Antineoplastic and Immunomodulating Agents	NA	Marburg virus	NA	NA	NA	Decrease (99 %)	Approved	24713118
DrugRepV_3707	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	NA	NA	NA	Decrease (0 %)	Approved	24713118
DrugRepV_3708	6-Azauridine	NA	Cancer	Ebola virus	NA	NA	NA	Decrease (99 %)	NA	24713118
DrugRepV_3709	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	NA	NA	NA	Decrease (99.9 %)	Approved	24713118
DrugRepV_3710	Imatinib Methanesulfonate Salt	Antineoplastic and Immunomodulating Agents	NA	Ebola virus	NA	NA	NA	Decrease (95 %)	Approved	24713118
DrugRepV_3715	C795-0925	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3716	D011-2120	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3717	F694-1532	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3718	G202-0362	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3719	C795-0925	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3720	D011-2120	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3721	F694-1532	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3722	G202-0362	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3735	OSU-03012	Anticancer	Brain cancer	Ebola virus	NA	NA	GFP assay	Decrease (50 %)	NA	25986249
DrugRepV_3736	OSU-03012	Anticancer	Brain cancer	Marburg virus	NA	NA	GFP assay	Decrease (50 %)	NA	25986249
DrugRepV_3739	Falnidamol dihydrochloride	NA	Solid Tumor	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	Investigational	25986249
DrugRepV_3740	Falnidamol dihydrochloride	NA	Solid Tumor	Marburg virus	NA	NA	RT-PCR	Decrease (50 %)	Investigational	25986249
DrugRepV_3743	OSU-03012	Anticancer	Brain cancer	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	25986249
DrugRepV_3744	Falnidamol	NA	Solid Tumor	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	Investigational	25986249
DrugRepV_3745	Falnidamol	NA	Solid Tumor	Ebola virus	1976	NA	Firefly luciferase assay	Decrease (50 %)	Investigational	25986249
DrugRepV_3746	Falnidamol	NA	Solid Tumor	Ebola virus	2014	NA	Firefly luciferase assay	Decrease (50 %)	Investigational	25986249
DrugRepV_3748	Amiodarone Hydrochloride	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	1976	NA	Firefly luciferase assay	Decrease (50 %)	Approved	25986249
DrugRepV_3749	Amiodarone Hydrochloride	Cardiovascular agents	Anginal and Arrhythmia	Ebola virus	2014	NA	Firefly luciferase assay	Decrease (50 %)	Approved	25986249
DrugRepV_3751	MLS000078751	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3752	MLS000394177	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3753	MLS000534476	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3754	MLS000554255	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3755	MLS000555232	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3756	MLS000730532	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3757	MLS000733230	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3758	MLS000762907	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3759	MLS001101371	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3760	MLS000078751	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3761	MLS000394177	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3762	MLS000534476	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3763	MLS000554255	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3764	MLS000555232	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3765	MLS000730532	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3766	MLS000733230	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3767	MLS000762907	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3768	MLS001101371	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3769	MLS001239325	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3770	MLS001239325	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3771	MLS001030162	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3772	MLS001030162	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3773	MLS000666802	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3774	MLS000666802	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3775	MLS000999960	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3776	MLS000999960	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3777	MLS001173370	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3778	MLS001173370	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3779	MLS001174896	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3780	MLS001174896	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3781	MLS001196083	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3782	MLS001196083	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3783	MLS001239358	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3784	MLS001239358	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3785	MLS001177927	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3786	MLS001177927	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3787	MLS001209453	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3788	MLS001209453	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3789	MLS000580080	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3790	MLS000580080	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3791	MLS000106706	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3792	MLS000106706	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3793	MLS001175455	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3794	MLS001175455	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3795	MLS000772389	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3796	MLS000772389	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3797	MLS000042810	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3798	MLS000042810	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3799	MLS001162808	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3800	MLS001162808	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3801	MLS000684231	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3802	MLS000684231	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3803	MLS000556387	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3804	MLS000556387	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3805	MLS001179278	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3806	MLS001179278	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3807	MLS000567464	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3808	MLS000567464	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3809	MLS000583959	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3810	MLS000583959	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3811	MLS001018888	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3812	MLS001018888	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3813	MLS001047402	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3814	MLS001047402	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3815	MLS001029946	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3816	MLS001029946	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3817	MLS000332573	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3818	MLS000332573	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3819	MLS000936259	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3820	MLS000936259	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3821	MLS000718690	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3822	MLS000718690	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3823	MLS000880330	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3824	MLS000880330	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3825	MLS001207131	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3826	MLS001207131	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3827	MLS000673118	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3828	MLS000673118	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3829	MLS000689481	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3830	MLS000689481	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3831	MLS001179272	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3832	MLS001179272	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3833	MLS002702500	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3834	MLS002702500	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3835	MLS001180408	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3836	MLS000737975	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3837	MLS001237534	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3838	MLS000336293	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3839	MLS000780111	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3840	MLS001179997	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3841	MLS000418057	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3842	MLS000936795	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3843	MLS000092187	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3844	MLS000391391	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3845	MLS000569139	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3846	MLS001045935	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3847	MLS001181479	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3848	MLS000391984	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3849	MLS000063146	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3850	MLS000768081	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3851	MLS000091920	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3852	MLS001150589	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3853	MLS000736237	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3854	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	Approved	27490565
DrugRepV_3855	Enclomiphene	NA	Male hypogonadism	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	Investigational	27490565
DrugRepV_3856	Zuclomiphene	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27490565
DrugRepV_3857	Clomiphene	Genito Urinary System and Sex Hormones	Polycystic ovary syndrome	Ebola virus	Mayinga	NA	Renilla luciferase assay	Decrease (100 %)	Approved	27490565
DrugRepV_3858	Enclomiphene	NA	Male hypogonadism	Ebola virus	Mayinga	NA	Renilla luciferase assay	Decrease (100 %)	Investigational	27490565
DrugRepV_3859	Zuclomiphene	NA	NA	Ebola virus	Mayinga	NA	Renilla luciferase assay	Decrease (100 %)	NA	27490565
DrugRepV_3860	Favipiravir	Antiviral	Influenza virus	Marburg virus	Leiden	NA	RT-PCR	Decrease (50 %)	Investigational	27736754
DrugRepV_3865	Favipiravir	Antiviral	Influenza virus	Ebola virus	Mayinga 1976	NA	MTT assay	Decrease (50 %)	Investigational	27736754
DrugRepV_3866	Favipiravir	Antiviral	Influenza virus	Ebola virus	Kikwit 1995/E718	NA	NA	Decrease (50 %)	Investigational	27736754
DrugRepV_3883	UV-1	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3884	UV-2	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3885	UV-3	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3886	UV-4	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3887	UV-5	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3888	UV-1	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3889	UV-2	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3890	UV-3	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3891	UV-4	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3892	UV-5	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3893	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3894	cp15	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3895	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3896	cp15	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3897	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3898	cp19	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3899	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3900	cp19	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3901	cp3	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3902	cp5	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3903	cp11	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3904	cp13	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3905	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3906	cp16	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3907	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3908	cp3	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3909	cp5	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3910	cp11	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3911	cp13	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3912	cp15	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3913	cp16	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3914	cp19	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3915	cp3	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3916	cp5	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3917	cp11	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3918	cp13	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3919	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3920	cp16	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3921	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3922	CBS1129	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3923	CBS1130	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3924	CBS1131	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3925	CBS1132	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3926	CBS1133	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3927	CBS1134	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3928	CBS1135	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3929	CBS1136	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3930	CBS1137	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3931	CBS1138	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3932	CBS1139	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3934	IHVR-19029	NA	NA	Ebola virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	29253498
DrugRepV_3935	Favipiravir	Antiviral	Influenza virus	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	Investigational	29289664
DrugRepV_3936	Favipiravir	Antiviral	Influenza virus	Ebola virus	Makona	NA	NA	Decrease (50 %)	Investigational	29289664
DrugRepV_3937	Favipiravir	Antiviral	Influenza virus	Marburg virus	Ci67	NA	NA	Decrease (50 %)	Investigational	29289664
DrugRepV_3938	GSK983	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3939	Angelicin	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3940	Benzoquinoline	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3941	SW539	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3942	SW320	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3943	SW351	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3944	SW491	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3945	SW490	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3946	SW388	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3947	SW386	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3948	SW349	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3949	SW991	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3950	SW456	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3951	Favipiravir	Antiviral	Influenza virus	Marburg virus	NA	NA	qRT-PCR	Decrease (50 %)	Investigational	29369776
DrugRepV_3952	Favipiravir	Antiviral	Influenza virus	Marburg virus	NA	NA	qRT-PCR	Decrease	Investigational	29369776
DrugRepV_3953	12N-p-dichlorobenzyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3954	12N-o-methylbenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3955	12N-2,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3956	12N-3,5 -dichlorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3957	12N-3,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3958	12N-m-methoxybenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3959	12N-benzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3960	12N-p-trifluoromethoxylbenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3961	12N-p-fluorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3962	12N-3,5-dichlorobenzoyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3963	12N-p-chlorobenzoyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3964	12N-3,4-dichlorobenzoyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3965	12N-3,4-dichlorobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3966	12N-3,5-dichlorobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3967	12N-o-thiophenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3968	12N-m-cyanobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3969	12N-p-chlorobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3970	12N-p-chlorophenylethyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3971	12N-3,4-dichlorophenylethyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3972	12N-3,5-dichlorophenylethyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3973	12N-3,4-dichlorohydrocinnamyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3974	12N-3,5-dichlorohydrocinnamyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3975	12N-p-chlorohydrocinnamyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3976	12N-p-dichlorobenzyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3977	12N-o-methylbenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3978	12N-2,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3979	12N-3,5 -dichlorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3980	12N-3,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3981	12N-m-methoxybenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3982	12N-benzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3983	12N-p-trifluoromethoxylbenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3984	12N-p-fluorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3985	12N-3,5-dichlorobenzoyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3986	12N-p-chlorobenzoyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3987	12N-3,4-dichlorobenzoyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3988	12N-3,4-dichlorobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3989	12N-3,5-dichlorobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3990	12N-o-thiophenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3991	12N-m-cyanobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3992	12N-p-chlorobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3994	Genistein	Antihelmintic	Prostate cancer	Marburg virus	NA	NA	Luciferase assay	Decrease (75 %)	Investigational	21947546
DrugRepV_3995	Genistein	Antihelmintic	Prostate cancer	Ebola virus	NA	NA	Luciferase assay	Decrease (87 %)	Investigational	21947546
DrugRepV_3997	Tyrphostin AG1478	NA	NA	Marburg virus	NA	NA	Luciferase assay	Decrease (100 %)	NA	21947546
DrugRepV_3998	Tyrphostin AG1478	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (100 %)	NA	21947546
DrugRepV_4000	Genistein-Tyrphostin AG1478	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (99 %)	NA	21947546
DrugRepV_4001	FGI-103	NA	NA	Ebola virus	Zaire	NA	Plaque assay	Decrease (50 %)	NA	20211898
DrugRepV_4002	FGI-103	NA	NA	Ebola virus	Sudan	NA	Plaque assay	Decrease (50 %)	NA	20211898
DrugRepV_4003	FGI-103	NA	NA	Marburg virus	Ravn	NA	Plaque assay	Decrease (50 %)	NA	20211898
DrugRepV_4004	FGI-103	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (95 %)	NA	20211898
DrugRepV_4005	FGI-103	NA	NA	Ebola virus	Zaire	NA	NA	Decrease	NA	20211898
DrugRepV_4088	Bafilomycin A1	Antibiotics	NA	Ebola virus	Mayinga	NA	Inhibition assay	Decrease (50 %)	Experimental	26069727
DrugRepV_4089	Bafilomycin A1	Antibiotics	NA	Ebola virus	Bundibugyo	NA	Inhibition assay	Decrease (50 %)	Experimental	26069727
DrugRepV_4090	Bafilomycin A1	Antibiotics	NA	Marburg virus	Lake Victoria isolate	NA	Inhibition assay	Decrease (50 %)	Experimental	26069727
DrugRepV_4092	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Mayinga	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4093	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Bundibugyo	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4094	Chloroquine	Malaria	Malaria	Marburg virus	Lake Victoria isolate	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4096	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Ebola virus	Bundibugyo	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4097	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Marburg virus	Lake Victoria isolate	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4099	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Ebola virus	Mayinga	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4100	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Ebola virus	Bundibugyo	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4101	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Marburg virus	Lake Victoria isolate	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4302	Carbocyclic adenosine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4303	Carbocyclic 3-deazaadenosine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4304	9-[trans- 2,trans - 3 - dihydroxy - 4 - (methyl) - cyclopent - 4 - enyl] - 3 - deazaadenine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4305	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-adenine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4306	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-3-deazaadenine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4307	9-[trans-2,trans-3-dihydroxycyclopent-4-enyl]- adenine (DHCpAdo)	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4308	9-[trans-2,trans-3-dihydroxycyclopent- 4-enyl]-3-deazaadenine (DHCp-c3Ado)	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4309	4,5- didehydro-5-deoxy-5-fluoroadenosine (DDFA)	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4310	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	Approved	9988190
DrugRepV_4311	Guanosine Dialdehyde	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4312	Adenosine Dialdehyde	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	Approved, Investigational	9988190
DrugRepV_4313	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	Sudan (Boneface strain)	NA	Plaque reduction assay	Decrease (50 %)	Approved	9988190
DrugRepV_4314	Carbocyclic 3-deazaadenosine	NA	NA	Ebola virus	Sudan (Boneface strain)	NA	Plaque reduction assay	Decrease (50 %)	NA	9988190
DrugRepV_4315	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-adenine	NA	NA	Ebola virus	Sudan (Boneface strain)	NA	Plaque reduction assay	Decrease (50 %)	NA	9988190
DrugRepV_4316	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-3-deazaadenine	NA	NA	Ebola virus	Sudan (Boneface strain)	NA	Plaque reduction assay	Decrease (50 %)	NA	9988190
DrugRepV_4317	Carbocyclic 3-deazaadenosine	NA	NA	Ebola virus	EBO-Z	NA	Survival assay	Increase	NA	9988190
DrugRepV_4318	FGI-106	NA	NA	Ebola virus	Zaire	NA	Plaque assay	Decrease (50 %)	NA	19523489
DrugRepV_4320	FGI-106	NA	NA	Ebola virus	Zaire	NA	Survival assay	Increase	NA	19523489
DrugRepV_4321	N-(1,3-benzodioxol-5-ylmethyl)-2-(3-cyano-2-methyl-1H-indol-1-yl)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (44.6 %)	NA	24501399
DrugRepV_4322	N-benzyl-6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (32.6 %)	NA	24501399
DrugRepV_4323	9H-carbazol-3-amine	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (6.1 %)	NA	24501399
DrugRepV_4324	7-(1H-benzimidazol-2-ylthio)-8-methyl[1,3]dioxolo[4,5-g]quinolin-6(5H)-one	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-3.8 %)	NA	24501399
DrugRepV_4325	N-[2-(2-methoxyethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-16 %)	NA	24501399
DrugRepV_4326	tris[4-(dimethylamino)phenyl]methanol	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (31.8 %)	NA	24501399
DrugRepV_4327	6-chloro-N-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-2-(3-pyridinyl)-4-quinolinecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (31.8 %)	NA	24501399
DrugRepV_4328	1-(2-furoyl)-5-(2-furyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-1.6 %)	NA	24501399
DrugRepV_4329	2-[(1H-benzimidazol-2-ylmethyl)thio]-1-[2-(4-methylphenoxy)ethyl]-1H-benzimidazole	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-1.8 %)	NA	24501399
DrugRepV_4330	N-(3-chloro-4-fluorophenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (66.3 %)	NA	24501399
DrugRepV_4331	4-{[(5-methyl-2-thienyl)methyl]amino}phenol	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-12.6 %)	NA	24501399
DrugRepV_4332	N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-1,3-benzodioxole-5-carboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-3.4 %)	NA	24501399
DrugRepV_4333	N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (10.2 %)	NA	24501399
DrugRepV_4334	2-methoxy-N-[1-methyl-2-(1-pyrrolidinylmethyl)-1H-benzimidazol-5-yl]benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (8.6 %)	NA	24501399
DrugRepV_4335	N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-(2-naphthyloxy)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (66.9 %)	NA	24501399
DrugRepV_4336	N-(2,5-dimethoxyphenyl)-N-[4-(trifluoromethyl)phenyl]urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (9.6 %)	NA	24501399
DrugRepV_4337	4-{[(1H-benzimidazol-2-ylthio)acetyl]amino}phenyl thiocyanate	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (34 %)	NA	24501399
DrugRepV_4338	N-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (11.6 %)	NA	24501399
DrugRepV_4339	N-1,3-benzodioxol-5-yl-6-chloro-2-(3-pyridinyl)-4-quinolinecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (45.7 %)	NA	24501399
DrugRepV_4340	N-(3-chlorophenyl)-N-(4-cyanophenyl)urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (10.1 %)	NA	24501399
DrugRepV_4341	N-[4-(1H-benzimidazol-2-yl)phenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-3.4 %)	NA	24501399
DrugRepV_4342	N-[3-(aminocarbonyl)-5-benzyl-2-thienyl]-2-methyl-3-furamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (5.7 %)	NA	24501399
DrugRepV_4343	4,5-dimethyl-2-{[(5-propyl-3-thienyl)carbonyl]amino}-N-(3-pyridinylmethyl)-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-24.6 %)	NA	24501399
DrugRepV_4344	1-(isopropylamino)-3-(3-phenyl-4,5-dihydropyrazolo[4,3-a]carbazol-10(3H)-yl)-2-propanol	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (13.1 %)	NA	24501399
DrugRepV_4345	2-[(4-tert-butyl-1,3-thiazol-2-yl)amino]-8-quinolinol	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (6.4 %)	NA	24501399
DrugRepV_4346	N-(aminocarbonyl)-2-{[(5-methyl-3-thienyl)carbonyl]amino}-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (6.2 %)	NA	24501399
DrugRepV_4347	2-chloro-N-(4-phenyl-1,3-thiazol-2-yl)-5-(4H-1,2,4-triazol-4-yl)benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (10.7 %)	NA	24501399
DrugRepV_4348	N-[3-(2-oxo-2H-chromen-3-yl)phenyl]-1,3-benzodioxole-5-carboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (2.1 %)	NA	24501399
DrugRepV_4349	4,5-dimethyl-2-[(phenoxyacetyl)amino]-N-(3-pyridinylmethyl)-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-0.6 %)	NA	24501399
DrugRepV_4350	N-(4-{[(5-methyl-3-isoxazolyl)amino]sulfonyl}phenyl)-1-benzothiophene-3-carboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-2.6 %)	NA	24501399
DrugRepV_4351	3-[(1H-benzimidazol-2-ylmethyl)thio]-9-benzyl-9H-[1,2,4]triazolo[4,3-a]benzimidazole	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-6.1 %)	NA	24501399
DrugRepV_4352	methyl N-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-N-cyanoglycinate	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (82.4 %)	NA	24501399
DrugRepV_4353	N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (33.4 %)	NA	24501399
DrugRepV_4354	N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (25.4 %)	NA	24501399
DrugRepV_4355	(1,3-benzodioxol-5-ylmethyl)[4-(1-pyrrolidinyl)phenyl]amine	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (10.5 %)	NA	24501399
DrugRepV_4356	4-methyl-5-phenyl-N-3-pyridinyl-2-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (25.2 %)	NA	24501399
DrugRepV_4357	N-(2,5-dimethoxyphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (17.4 %)	NA	24501399
DrugRepV_4358	3-[(2,4-dichlorophenoxy)methyl]-N-(3-pyridinylmethyl)benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (26.8 %)	NA	24501399
DrugRepV_4359	5-phenyl-2-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-6.6 %)	NA	24501399
DrugRepV_4360	6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (20.9 %)	NA	24501399
DrugRepV_4361	2-[(2-methyl-8-quinolinyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-12.1 %)	NA	24501399
DrugRepV_4362	N-(3-chloro-4-fluorophenyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (12.3 %)	NA	24501399
DrugRepV_4363	4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)-N-methylbenzenesulfonamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (1.8 %)	NA	24501399
DrugRepV_4364	2-(4-fluorophenyl)-N-(4-{[(4-methylphenyl)amino]sulfonyl}phenyl)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (1.1 %)	NA	24501399
DrugRepV_4365	5-methyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-0.3 %)	NA	24501399
DrugRepV_4366	2-amino-N-(3-chlorophenyl)-3-quinolinecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-1.5 %)	NA	24501399
DrugRepV_4367	2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-15.9 %)	NA	24501399
DrugRepV_4368	N-{3-[(benzylamino)carbonyl]phenyl}-5-methyl-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-11.5 %)	NA	24501399
DrugRepV_4369	8-chloro-N-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-2-(2-pyridinyl)-4-quinolinecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-11.7 %)	NA	24501399
DrugRepV_4370	N-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(2-thienyl)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (8.05 %)	NA	24501399
DrugRepV_4471	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4472	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-Gluc	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4473	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4474	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4475	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4476	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4477	Brincidofovir	Antiviral	Viral infections	Ebola virus	EBOV-GFP	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4478	Brincidofovir	Antiviral	Viral infections	Ebola virus	Mayinga	NA	Operetta High Content Imaging System	Decrease (50 %)	Investigational	26526586
DrugRepV_4479	Brincidofovir	Antiviral	Viral infections	Ebola virus	Makona	NA	NA	Decrease (50 %)	Investigational	26526586
DrugRepV_4480	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Kikwit	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4481	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Kikwit	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4482	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Kikwit	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4483	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Makona	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4484	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Makona	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4485	Brincidofovir	Antiviral	Viral infections	Ebola virus	Ebola Zaire Makona	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4486	Brincidofovir	NA	Viral infections	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4487	CMX029	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4488	CMX021	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4489	CMX028	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4490	CMX16669	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4491	CMX16663	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4492	CMX167	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4493	CMX157	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4494	CMX101	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4495	CMX004	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4496	CMX16689	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4497	Ranpirnase	Anticancer	Cancer	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	Investigational	27350309
DrugRepV_4498	Ranpirnase	Anticancer	Cancer	Ebola virus	Kikwit	NA	Fluorescence-based assay	Decrease	Investigational	27350309
DrugRepV_4499	Ranpirnase	Anticancer	Cancer	Ebola virus	Kikwit	NA	NA	Increase	Investigational	27350309
DrugRepV_4500	(1S,2R,5S)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4501	(1S,2R,5R)-5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4502	(1S,2R,5R)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4503	(1R,2S,5R)-3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4504	(1R,2S,5R)-3-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4505	(1S,2R,5S)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4506	(1S,2R,5R)-5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4507	(1S,2R,5R)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4508	(1R,2S,5R)-3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4509	(1R,2S,5R)-3-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4510	(1S,2R,5S)-5-(6-amino-9H-purin-9-yl)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4512	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Increase	Investigational	30275474
DrugRepV_4513	Remdesivir	Antiviral	Hepatitis C | Ebola	Ebola virus	NA	NA	NA	Increase	Experimental	30275474
DrugRepV_4514	Favipiravir	Antiviral	Influenza virus	Ebola virus	NA	NA	NA	Increase	Investigational	29584730
DrugRepV_4822	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4823	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4824	Dalbavancin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4825	Oritavancin	Antiinfectives For Systemic Use	Acute bacterial skin | Skin structure infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4826	Telavancin	Antiinfectives For Systemic Use	Skin infections (Bacterial)	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4827	Vancomycin	Alimentary Tract and Metabolism; Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4828	CTSL inhibitor	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	26953343
DrugRepV_5192	C795-0925	NA	NA	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5193	D011-2120	NA	NA	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5194	F694-1532	NA	NA	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5195	G202-0362	NA	NA	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5196	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	Approved	25144302
DrugRepV_5197	C795-0925	NA	NA	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5198	D011-2120	NA	NA	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5199	F694-1532	NA	NA	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5200	G202-0362	NA	NA	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5201	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	Approved	25144302
DrugRepV_5327	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarbonitrile	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5328	diethyl {[2-(4,5-dicyano-1H-imidazol-1-yl)ethoxy]methyl}phosphonate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5329	diethyl {2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl}phosphonate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5330	1-[(2-bromoethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5331	2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl acetate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5332	1-[(2-hydroxyethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5333	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5334	{2-[4,5-bis(methoxycarbonyl)-1H-imidazol-1-yl]ethoxy}phosphonic acid	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5335	4,5-dimethyl 1-[(2R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5336	4,5-dimethyl 1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5337	4,5-dimethyl 1-[2-(acetyloxy)ethyl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5338	4,5-dimethyl 1-[(2R,5S)-3,4-bis(acetyloxy)-5-[(acetyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5339	4,5-dimethyl 1-[(2R,5S)-3,4-bis(benzoyloxy)-5-[(benzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5340	4,5-dimethyl 1-[(2R,5S)-4-(4-methylbenzoyloxy)-5-[(4-methylbenzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5341	1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5342	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5343	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbohydrazide	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5344	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxamide	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5349	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5350	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5351	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5352	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5357	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5358	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5359	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5360	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5365	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	Approved	21616094
DrugRepV_5366	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	Approved	21616094
DrugRepV_5367	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	Approved	21616094
DrugRepV_5368	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	Approved	21616094
DrugRepV_5373	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	Approved	21616094
DrugRepV_5374	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	Approved	21616094
DrugRepV_5375	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	Approved	21616094
DrugRepV_5376	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	Approved	21616094
DrugRepV_5383	8-Azaadenosine	NA	NA	Ebola virus	Ebola virus/H.sapiens-rec/LBR/2014/ Makona-L2014	NA	Minigenome assays	Decrease (50 %)	NA	27771389
DrugRepV_5384	Toyocamycin	NA	NA	Ebola virus	Ebola virus/H.sapiens-rec/LBR/2014/ Makona-L2015	NA	Minigenome assays	Decrease (50 %)	Experimental	27771389
DrugRepV_5385	6-Azauridine	NA	Cancer	Ebola virus	Ebola virus/H.sapiens-rec/LBR/2014/ Makona-L2016	NA	Minigenome assays	Decrease (50 %)	NA	27771389
DrugRepV_5386	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	NA	NA	qRT-PCR	Decrease	Investigational	31307979
DrugRepV_5388	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5394	Zoniporide	NA	NA	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	NA	30700611
DrugRepV_5396	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5398	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5400	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5402	Arbidol	NA	Viral infection	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5404	Clomiphene	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5406	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5408	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved, Investigational	30700611
DrugRepV_5491	Amodiaquine Dihydrochloride Dihydrate	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	Approved, Investigational	31882748
DrugRepV_5492	Amodiaquine Dihydrochloride Dihydrate	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	Approved, Investigational	31882748
DrugRepV_5493	Amodiaquine Dihydrochloride Dihydrate	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	Approved, Investigational	31882748
DrugRepV_5494	Artesunate	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	Approved, Investigational	31882748
DrugRepV_5495	Winthrop	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5496	Winthrop	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5497	Winthrop	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5498	N-Desethylamodiaquine hydrochloride	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5499	N-Desethylamodiaquine hydrochloride	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5500	N-Desethylamodiaquine hydrochloride	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5501	Dihydroartimesinin	NA	Malaria	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	Experimental, Investigational	31882748
DrugRepV_5502	Dihydroartimesinin	NA	Malaria	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	Experimental, Investigational	31882748
DrugRepV_8294	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8295	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8296	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892
DrugRepV_8297	Tolcapone	Nervous System	Parkinson's Disease	Ebola virus	NA	NA	NA	Decrease (50 %)	Approved, Withdrawn	32425892